Regeneus receives A$1.5 million in R&D Tax Incentives
Filed with ASX · · 1 page · English
Earlier from Cambium Bio
- Appendix 4E
- Restructuring results in 50% reduction in operating costs
- Updated Investor Presentation
- Offer Booklet
- Investor Presentation
Later from Cambium Bio
- Japanese Biotech Fund takes up all Rights Issue Shortfall
- Chairmans Address to Shareholders
- CEO Presentation to 2019 Annual General Meeting
- AGC Agreement termination paves way for commercial partner
- Directors provide $4m loan facility
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio